Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708507 | 1.00 | TSHR (0.42) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL17830151 | 0.89 | — | — | |
| SCHEMBL29449241 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL29449225 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL29449268 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL29449253 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL29449256 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL6027614 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL21385113 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 | |
| SCHEMBL29449258 | 0.81 | TSHR (0.44) | TSHRTHRBEPHX1DNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009059984-A2 | REVERSIBLE HYDROPHOBIZATION OF ANTITUMOR DRUGS FOR ENHANCED FIRST-PASS DRUG UPTAKE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090074885-A1 | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells | ROCHE MADISON INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1663933-A2 | IMPROVED DELIVERY BY LABILE HYDROPHOBIC MODIFICATION OF DRUGS | Mirus Bio Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026083-A2 | IMPROVED DELIVERY BY LABILE HYDROPHOBIC MODIFICATION OF DRUGS | MIRUS BIO CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054612-A1 | Delivery by labile hydrophobic modification of drugs | ROCHE MADISON INC. | 2005-03-10 | — | — | US | disclosed |